NSEUpdates4d ago · 1 Sept 2026, 05:24 pm
Updates
Thyrocare Technologies Limited · THYROCARE
✦ AI SummaryM&A
Thyrocare Technologies Limited has informed the Exchange regarding the approval of the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited by the Hon'ble National Company Law Tribunal, Mumbai Bench.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Thyrocare Technologies Limited has informed the Exchange regarding Communication Received from API Holdings Limited regarding Approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited
Attachments (1)
📄pdf
Download →
THYROCARE_01092026172441_SE_Intimation-Reg-30_signed.pdf
View document text
September 01, 2026
National Stock Exchange of India Limited BSE Limited
Exchange Plaza, C-1, Phiroze Jeejeebhoy Towers,
Block G, Bandra Kurla Complex, Dalal Street, Mumbai- 400001
Bandra (E), Mumbai – 400051
Sub: Communication received from API Holdings Limited regarding approval of Scheme of
Amalgamation of Docon Technologies Private Limited with API Holdings Limited
Ref: Scheme of Amalgamation of Docon Technologies Private Limited (“Transferor Company”), API
Holdings Limited (“Transferee Company”) and their respective Shareholders under the
provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
Dear Sir/Madam,
We wish to inform you that Docon Technologies Private Limited ("Docon" or the "Transferor
Company") and API Holdings Limited ("API" or the "Transferee Company") had filed a Scheme of
Amalgamation of Docon with API, along with their respective shareholders ("the Scheme"), before the
Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT"), under Sections 230 to 232 and
other applicable provisions of the Companies Act, 2013.
We are pleased to inform you that the Hon'ble NCLT, Mumbai Bench, vide its order pronounced on
August 31, 2026, has sanctioned the aforesaid Scheme of Amalgamation. A copy of the said Order is
available on the website of the Hon'ble NCLT at https://nclt.gov.in/.
As per the Scheme, the Scheme shall become operative upon the "Effective Date", which is the date
when all conditions precedent, including filing of the certified copy of the NCLT Order with the
Registrar of Companies (“RoC”) in Form No. INC-28, are completed or duly waived. Docon and API shall
file the certified copy of the NCLT Order with the RoC within the prescribed timelines.
Upon the Scheme becoming effective, Docon shall stand amalgamated with API, and all assets,
liabilities, undertakings, rights and obligations of Docon shall stand transferred to and vested in API in
accordance with the provisions of the Scheme. Consequently, Docon’s entire shareholding in the
Company, comprising 8,12,00,000 equity shares, representing 51.02% of the paid-up share capital of
the Company, shall, by operation of law, stand transmitted and vested to API on the Effective Date.
It is further clarified that Docon is a wholly owned subsidiary of API. Both, Docon and API are presently
members of the Promoter Group of the Company. Upon the transmission and vesting of Docon’s
shareholding in the Company to API on the Effective Date, there shall be no change in the aggregate
shareholding of the Promoter and Promoter Group of the Company, which shall continue to be 51.02%.
The said shareholding shall be held by API, being a member of the Promoter Group, post the Effective
Date, in place of Docon.
The shareholding pattern before and after implementation of the Scheme is set out in the table below:
Before Scheme After Scheme implementation
Implementation
S. No Category of No of Shares %of holding No of Shares %of holding
Shareholders
A) Promoter & Promoter
Group
1 Docon Technologies 8,12,00,000 51.02% Nil Nil
Private Limited
2 API Holdings Limited Nil Nil 8,12,00,000 51.02%
B) Public Shareholders 7,79,65,315 48.98% 7,79,65,315 48.98%
Total (A+B) 15,91,65,315 100.00% 15,91,65,315 100.00%
The Company is submitting this intimation to the Stock Exchanges for information and records.
Yours Faithfully,
For Thyrocare Technologies Limited,
Brijesh Kumar
Company Secretary and Compliance Officer